Tags

Type your tag names separated by a space and hit enter

Leg ulcers and hydroxyurea: forty-one cases.
Arch Dermatol. 1999 Jul; 135(7):818-20.AD

Abstract

BACKGROUND

Hydroxyurea is an antitumor agent used to treat chronic myeloproliferative disorders. Leg ulcerations have been reported in patients undergoing long-term hydroxyurea therapy for myeloproliferative diseases. To better define this dermatological adverse effect of hydroxyurea therapy and to try to understand the pathophysiological process of this disease, we collected medical information for such patients in a multicenter retrospective study.

OBSERVATIONS

Forty-one patients (mean age, 67 years) developed leg ulcerations while undergoing hydroxyurea therapy (mean therapy duration, 5 years). The sex ratio was 1, and there was no underlying vascular disease. Hematologic abnormalities were identified. Complete recovery from the ulcerations occurred quickly after withdrawal of treatment in 33 (80%) of the cases.

CONCLUSIONS

This longest-reported series of patients confirms the role of hydroxyurea therapy in the onset of leg ulcerations. Healing or improvement requires cessation of treatment. Cutaneous atrophy and impaired wound healing may explain the relationship between hydroxyurea and leg ulcers. In addition, the megaloblastic erythrocytes resulting from the presence of hydroxyurea may circulate poorly through the capillary network. A prospective study in hematologic centers would be valuable.

Authors+Show Affiliations

Rééducation Vasculaire, Hôpital Broussais, Paris, France. marie-emmanuelle.sirieix-h@brs.ap-hop-paris.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10411157

Citation

Sirieix, M E., et al. "Leg Ulcers and Hydroxyurea: Forty-one Cases." Archives of Dermatology, vol. 135, no. 7, 1999, pp. 818-20.
Sirieix ME, Debure C, Baudot N, et al. Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol. 1999;135(7):818-20.
Sirieix, M. E., Debure, C., Baudot, N., Dubertret, L., Roux, M. E., Morel, P., Frances, C., Loubeyres, S., Beylot, C., Lambert, D., Humbert, P., Gauthier, O., Dandurand, M., Guillot, B., Vaillant, L., Lorette, G., Bonnetblanc, J. M., Lok, C., & Denoeux, J. P. (1999). Leg ulcers and hydroxyurea: forty-one cases. Archives of Dermatology, 135(7), 818-20.
Sirieix ME, et al. Leg Ulcers and Hydroxyurea: Forty-one Cases. Arch Dermatol. 1999;135(7):818-20. PubMed PMID: 10411157.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Leg ulcers and hydroxyurea: forty-one cases. AU - Sirieix,M E, AU - Debure,C, AU - Baudot,N, AU - Dubertret,L, AU - Roux,M E, AU - Morel,P, AU - Frances,C, AU - Loubeyres,S, AU - Beylot,C, AU - Lambert,D, AU - Humbert,P, AU - Gauthier,O, AU - Dandurand,M, AU - Guillot,B, AU - Vaillant,L, AU - Lorette,G, AU - Bonnetblanc,J M, AU - Lok,C, AU - Denoeux,J P, PY - 1999/7/20/pubmed PY - 1999/7/20/medline PY - 1999/7/20/entrez SP - 818 EP - 20 JF - Archives of dermatology JO - Arch Dermatol VL - 135 IS - 7 N2 - BACKGROUND: Hydroxyurea is an antitumor agent used to treat chronic myeloproliferative disorders. Leg ulcerations have been reported in patients undergoing long-term hydroxyurea therapy for myeloproliferative diseases. To better define this dermatological adverse effect of hydroxyurea therapy and to try to understand the pathophysiological process of this disease, we collected medical information for such patients in a multicenter retrospective study. OBSERVATIONS: Forty-one patients (mean age, 67 years) developed leg ulcerations while undergoing hydroxyurea therapy (mean therapy duration, 5 years). The sex ratio was 1, and there was no underlying vascular disease. Hematologic abnormalities were identified. Complete recovery from the ulcerations occurred quickly after withdrawal of treatment in 33 (80%) of the cases. CONCLUSIONS: This longest-reported series of patients confirms the role of hydroxyurea therapy in the onset of leg ulcerations. Healing or improvement requires cessation of treatment. Cutaneous atrophy and impaired wound healing may explain the relationship between hydroxyurea and leg ulcers. In addition, the megaloblastic erythrocytes resulting from the presence of hydroxyurea may circulate poorly through the capillary network. A prospective study in hematologic centers would be valuable. SN - 0003-987X UR - https://www.unboundmedicine.com/medline/citation/10411157/Leg_ulcers_and_hydroxyurea:_forty_one_cases_ L2 - https://jamanetwork.com/journals/jamadermatology/fullarticle/vol/135/pg/818 DB - PRIME DP - Unbound Medicine ER -